Optimising heart failure treatment: real-world prescription patterns and guideline adherence in Singapore
Year: 2026
Type: article
Abstract: The 2022 American Heart Association and the 2021 European Society of Cardiology guidelines for the management of heart failure with reduced ejection fraction advocate for a combination of four drug classes, referred to as quadruple therapy. This includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor neprilysin inhibitors; beta-blockers; mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Despite clear recommendations, real-world adherence often falls short. This study examines trends in heart failure treatment in Singapore from 2017 to 2022. A cross-sectional descriptive study was conducted using data from patients with heart failure with reduced ejection fraction across five tertiary care hospitals in Singapore. Administrative records were extracted from the Singapore Cardiovascular Longitudinal Outcomes Database. The analysis included prescription patterns of heart failure therapies, dosage adherence to guideline-recommended target doses, and factors influencing drug choices. Generalized linear mixed models and multinomial logit models were employed to assess determinants of drug prescription. The study included 6,578 patients with a median age of 71 years, 70.2% of whom were male. The majority were of Chinese (62.6%), and the mean left ventricular ejection fraction was 28%. Quadruple therapy increased from 0% in 2017 to 14.5% in 2022. Triple therapy was prescribed in 23.8% of patients in 2022, with the most common combination being an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or angiotensin receptor neprilysin inhibitor, combined with a beta-blocker and a mineralocorticoid receptor antagonist. Dual therapy was used in 23.7%, most frequently an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or angiotensin receptor neprilysin inhibitor, combined with a beta-blocker. However, monotherapy and non-use of any recommended drug remained significant at 25.9% and 12.1%, respectively. Around 80% of patients on angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or angiotensin receptor neprilysin inhibitors and 60% on beta-blockers received less than 50% of the guideline-recommended doses, while 95% of patients on sodium-glucose cotransporter 2 inhibitors received the recommended fixed target dose. Factors associated with lower drug prescription included advanced age, chronic kidney disease, and palliative care. Institutional variations in prescription patterns were also observed. Despite a gradual increase in the uptake of quadruple therapy, its use remains substantially below guideline expectations, highlighting a persistent gap in the implementation of guideline-directed medical therapy in Singapore.
Source: BMC Health Services Research
Authors: Sameera Senanayake, Audry Shan Yin Lee, Phoo Pyae Sone Win, Chun Fan Lee, Sanjeewa Kularatna, Annie Lee, Yee How Lau, Derek J. Hausenloy, Khung-Keong Yeo, Mark Yan-Yee Chan, Raymond Ching Chiew Wong, Seet Yoong Loh, Kheng Leng David Sim, Chow Weien, Doreen Su-Yin Tan, Kelvin Bryan Tan, Nicholas Graves
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W7237240503
